MorphoSys AG: Corporate Calendar 2020

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Return to homepage

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / December 12, 2019 / MorphoSys (NASDAQ:MOR) (FSE:MOR):

Dear Madam/Sir,

Please note MorphoSys's financial reporting dates 2020 as follows:

For a direct import of the dates to your calendar, please visit our corporate website: https://www.morphosys.com/media-and-investors/morphosys-events#company-calendar

With season's greetings and good wishes for the New Year:
www.morphosys.com/xmas-2019

About MorphoSys

MorphoSys (FSE & NASDAQ: MOR) is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of exceptional, innovative therapies for patients suffering from serious diseases. The focus is on cancer. Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, of which 28 are currently in clinical development. In 2017, Tremfya(R), marketed by Janssen for the treatment of plaque psoriasis, became the first drug based on MorphoSys's antibody technology to receive regulatory approval. The Company's most advanced proprietary product candidate, tafasitamab (MOR208), has been granted U.S. FDA breakthrough therapy designation for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Headquartered near Munich, Germany, the MorphoSys group, including the fully owned U.S. subsidiary MorphoSys US Inc., has approximately 405 employees. More information at https://www.morphosys.com.

HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R), arYla(R), Ylanthia(R), 100 billion high potentials(R), Slonomics(R), Lanthio Pharma(R), LanthioPep(R) and ENFORCERTM are trademarks of the MorphoSys Group. Tremfya(R) is a trademark of Janssen Biotech, Inc.

Publication of Interim Statement / ReportConference Call
Year-End Results 2019March 18, 2020 // 10 pm CET
(5 pm EDT; 9 pm GMT)		March 19, 2019 // 2 pm CET
(9 am EDT; 1 pm GMT)
First Quarter Interim Statement 2020May 6, 2020 // 10 pm CEST
(4 pm EDT; 9 pm BST)		May 7, 2020 // 2 pm CEST
(8 am EDT; 1 pm BST)
Half-Year Report 2020Aug. 5, 2020 // 10 pm CEST
(4 pm EDT; 9 pm BST)		Aug. 6, 2020 // 2 pm CEST
(8 am EDT; 1 pm BST)
Third Quarter Interim Statement 2020Nov. 11, 2020 // 10 pm CET
(4 pm EST; 9 pm GMT)		Nov. 12, 2020 // 2 pm CET
(8 am EST; 1 pm GMT)
Annual General MeetingMay 27, 2020


For more information, please contact:
MorphoSys AG

Dr. Sarah Fakih
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-26663
[email protected]

Dr. Julia Neugebauer
Director Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-179
[email protected]

Dr. Verena Kupas
Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-26814
[email protected]

SOURCE: MorphoSys



View source version on accesswire.com:
https://www.accesswire.com/570039/MorphoSys-AG-Corporate-Calendar-2020

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).
LinkedIn
StockTwits
Twitter